About
Peter Hamley is a UK biotech executive and scientist focused on drug discovery. As of November 2025, he is founder and CEO of Scripta Therapeutics, an Oxford techbio company developing disease-modifying drugs by modulating transcription factor activity. Earlier public profiles describe him as Chief Scientific Officer of Samsara Therapeutics and an Advisory Board Member at UKI2S, with prior experience at AstraZeneca and Sanofi.
Areas of interest
biotechtechbioAI drug discoveryneurodegenerationautophagylife sciencestranscription factor biology